Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.
3.

Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration.

Kwak HB, Lee SW, Jin HM, Ha H, Lee SH, Takeshita S, Tanaka S, Kim HM, Kim HH, Lee ZH.

Blood. 2005 Apr 1;105(7):2963-9. Epub 2004 Dec 7.

4.

Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis.

Fox SW, Chambers TJ.

Biochem Biophys Res Commun. 2000 Oct 5;276(3):868-72.

PMID:
11027561
5.

RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells.

Pang M, Martinez AF, Jacobs J, Balkan W, Troen BR.

Biochem Biophys Res Commun. 2005 Mar 18;328(3):756-63.

PMID:
15694411
6.

Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.

Hayashi S, Yamada T, Tsuneto M, Yamane T, Takahashi M, Shultz LD, Yamazaki H.

J Immunol. 2003 Nov 15;171(10):5130-9.

7.

MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival.

Okamatsu Y, Kim D, Battaglino R, Sasaki H, Sp├Ąte U, Stashenko P.

J Immunol. 2004 Aug 1;173(3):2084-90.

8.

T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms.

Weitzmann MN, Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R.

J Bone Miner Res. 2001 Feb;16(2):328-37.

9.

Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis.

De Klerck B, Carpentier I, Lories RJ, Habraken Y, Piette J, Carmeliet G, Beyaert R, Billiau A, Matthys P.

Arthritis Res Ther. 2004;6(3):R220-31. Epub 2004 Mar 12.

10.

Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.

Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW.

Endocrinology. 2001 Sep;142(9):3800-8.

PMID:
11517156
12.

TGF-beta 1 and IFN-gamma direct macrophage activation by TNF-alpha to osteoclastic or cytocidal phenotype.

Fox SW, Fuller K, Bayley KE, Lean JM, Chambers TJ.

J Immunol. 2000 Nov 1;165(9):4957-63.

13.

Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.

Enomoto H, Shiojiri S, Hoshi K, Furuichi T, Fukuyama R, Yoshida CA, Kanatani N, Nakamura R, Mizuno A, Zanma A, Yano K, Yasuda H, Higashio K, Takada K, Komori T.

J Biol Chem. 2003 Jun 27;278(26):23971-7. Epub 2003 Apr 15.

14.
15.

T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.

Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T.

Nature. 2000 Nov 30;408(6812):600-5.

PMID:
11117749
17.

Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes.

Shinoda K, Sugiyama E, Taki H, Harada S, Mino T, Maruyama M, Kobayashi M.

Bone. 2003 Oct;33(4):711-20.

PMID:
14555277
18.

Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.

Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, Higashio K, Quinn JM, Gillespie MT, Martin TJ, Suda T, Takahashi N.

Endocrinology. 2001 Aug;142(8):3656-62.

PMID:
11459815
19.

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.

Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL.

J Clin Invest. 2000 Dec;106(12):1481-8.

20.

Flt3+ macrophage precursors commit sequentially to osteoclasts, dendritic cells and microglia.

Servet-Delprat C, Arnaud S, Jurdic P, Nataf S, Grasset MF, Soulas C, Domenget C, Destaing O, Rivollier A, Perret M, Dumontel C, Hanau D, Gilmore GL, Belin MF, Rabourdin-Combe C, Mouchiroud G.

BMC Immunol. 2002 Oct 24;3:15.

Supplemental Content

Support Center